MaxCyte, Inc.

NASDAQ:MXCT

Medical - Devices

Healthcare
$1.25 +3.98%

+$0.05 today

Market cap
$129.06M
Beta
1.67
P/E (TTM)
-3.2
EPS (TTM)
-$0.37
52W Low $0.64High $2.37

Volume 0.97M

Average 0.95M

MXCT Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

MaxCyte, Inc.NASDAQ: MXCT

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue falls 21.1% from a year ago

Deferred revenue stood at $3.27M at the end of Q1 FY2026, down 21.1% from a year earlier and down 9.1% from the prior quarter.

Context

  • Deferred revenue amounted to 1.7% of total assets at the end of Q1 FY2026, down 0.1 pp from a year earlier.
  • Deferred revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether deferred revenue keeps falling in the next quarterly balance sheet after a -21.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.27M-9.1% QoQ
Last fiscal yearDec 2025
$3.6M-31.5% YoY
Year agoMar 2025
$4.15M-21.1% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.1%——
1 year-31.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
3.6M USD
Year-over-year change
-31.5%
4-year CAGR
-14.5%

Deferred Revenue vs competitors

How MXCT compares with its peers on the latest reported figures

  • MXCT's Mar 2026 deferred revenue of $3.27M is the 2nd highest of the 11 companies compared; the peer median is $499.76K.
  • Its year-over-year change of -21.1% is the 4th highest of 7, against a peer median of +12.2%.
  • Deferred revenue amounts to 1.7% of total assets for MXCT, versus a peer median of 0.7%.
MXCT Competitors Peer median
Deferred Revenue for MXCT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CATXPerspective Therapeutics, Inc.Mar 2026$26.6M ——6.5%
MXCTMaxCyte, Inc.Mar 2026$3.27M -21.1%—1.7%
LNSRLENSAR, Inc.Mar 2026$3.01M +51.2%+58.8%4.5%
PREPrenetics Global LimitedMar 2026$2.95M -52.4%-18.4%1.7%
OWLTOwlet, Inc.Mar 2026$2.41M +65.3%—2.8%
NNOXNano-X Imaging Ltd.Dec 2025$534K +281.4%+43.2%0.3%
PROFProfound Medical Corp.Mar 2026$465.53K -26.8%—0.6%
SGMOSangamo Therapeutics, Inc.Mar 2026$402K -94.7%-74.1%0.7%
AVRAnteris Technologies Global Corp.Mar 2026$0 ——0.0%
TLSITriSalus Life Sciences, Inc.Mar 2026$0 ——0.0%
ARMPArmata Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
Peer median (excluding MXCT) $499.76K+12.2%+12.4%0.7%

Competitors are the stored peer set for MXCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents47.78M11.07M46.51M27.88M20.07M
Short-term Investments207.26M216.28M121.78M126.6M82.98M
Net Receivables6.88M11.18M5.78M4.68M3.5M
Inventory5.2M8.58M12.23M8.91M7.55M
Other Current Assets01.91M3.9M3.61M4.28M
Total Current Assets270.43M252.27M190.19M171.68M118.37M
Property, Plant & Equipment (Net)13.37M33.58M34.75M30.47M28.45M
Goodwill00000
Intangible Assets0000650K
Long-term Investments0042.94M35.78M52.57M
Tax Assets00000
Other Non-current Assets316.7K809K388K1.53M2.47M
Total Non-current Assets13.69M34.39M78.08M67.79M84.14M
Total Assets284.12M286.65M268.27M239.47M202.51M
Account Payables1.82M292K743K1.36M1.4M
Short-term Debt000864K1.46M
Tax Payables00000
Deferred Revenue6.75M05.07M5.25M3.6M
Other Current Liabilities06.71M08.3M7.81M
Total Current Liabilities15.62M15.43M17.86M15.78M14.27M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities450.2K1.32M283K274K263K
Total Non-current Liabilities5.61M17.26M18.25M17.44M16.75M
Total Liabilities21.22M32.69M36.11M33.22M31.02M
Common Stock1.01M1.02M1.04M1.06M1.07M
Retained Earnings(114.3M)(137.88M)(175.8M)(216.85M)(261.48M)
Accumulated OCI0(0)000
Other Stockholders Equity00000
Minority Interest00000
Total Equity262.9M253.97M232.17M206.25M171.49M
Total Debt5.68M16.1M18.74M18.03M17.94M
Net Debt(42.1M)5.03M(27.76M)(9.85M)(2.12M)

MaxCyte, Inc.

NASDAQ:MXCT

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.